Close Menu

NEW YORK – Despite the potential cancer detection and treatment benefits of identifying individuals at risk of hereditary breast and ovarian cancer (HBOC), many individuals who meet National Comprehensive Cancer Network (NCCN) guidelines for testing still aren't receiving it.

And for patients from understudied, non-European populations, access to testing is just the start: those individuals may also contend with unappreciated genetic contributors to cancer risk, more frequent variants of uncertain significance and other potential barriers to appropriate testing and interpretation.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Oct
23

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.